Reports
Global Liquid Biopsy Market Size, Analysis, Forecast: By Application: Therapy Selection for Metastatic Breast Cancer, Therapy Selection for Other Metastatic Cancer, Molecular Health Monitoring; By Sample Type: Blood Sample Based, Urine Sample Based, Others; By Biomarker; By Technology; Regional Analysis; Competitive Landscape; 2024-2032
Global Liquid Biopsy Market Outlook
The global liquid biopsy market stood at a value of around USD 2,269.81 million in 2023. The market is further expected to grow at a CAGR of 22% in the forecast period of 2024-2032 to attain a value of USD 13,591.48 million by 2032.
Circulating Tumour DNA Segment to Aid the Overall Growth of the Global Liquid Biopsy Industry
Based on the biomarker, the circulating tumour DNA segment is estimated to hold a considerable share in the global liquid biopsy industry during the forecast period. This growth can be attributed to the rapid technological advancements, such as the application of next-generation sequencing technologies in the liquid biopsy process for the circulating tumour DNA biomarker analysis.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Furthermore, in terms of application, the therapy selection for the metastatic breast cancer segment is expected to observe a significant increase due to the promising results yielded in the variety of studies analysing the scope of liquid biopsies. Liquid biopsy contributed especially in the process of treatment response monitoring and disease progression estimation for breast cancers.
The Asia Pacific Region to Account for a Significant Share in the Global Liquid Biopsy Industry
The Asia Pacific region is predicted to possess a significant share of the global liquid biopsy industry. This surge can be attributed to the rising incidences of cancer in the region. According to Global Cancer Statistics 2020 issued by GLOBOCAN, the Asia Pacific region accounted for 58.3% of the overall cancer death worldwide. In addition, governments are increasingly investing in the development of the healthcare infrastructure and the advancement of liquid biopsy profiling methodologies, which is expected to further contribute to the market growth in the region.
Liquid Biopsy: Market Segmentation
Liquid biopsy is a non-invasive method, as opposed to surgical biopsy, in tumour molecular profiling, where a doctor need not obtain the tumour tissue directly. Instead, physicians can analyse the biomarkers, that is, circulating tumour cells and circulating cell-free tumour DNA present in the blood drawn from a person's arm or a urine sample to detect and characterise tumours. This method is useful in the early detection of cancer and helps monitor the tumour growth and assess the clinical approach to be taken in terms of treatment.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
By application, the market is distributed into:
- Therapy Selection for Metastatic Breast Cancer
- Therapy Selection for Other Metastatic Cancer
- Molecular Health Monitoring
On the basis of sample type, the industry can be categorised into:
- Blood Sample Based
- Urine Sample Based
- Others
Based on biomarker, the market can be segmented into:
- Circulating Tumour Cells
- Circulating Tumour DNA
- Exosomes
On the basis of technology, the industry can be bifurcated into:
- Multi-Gene-Parallel Analysis Using NGS
- Single Gene Analysis Using PCR Microarrays
The regional markets for the product include North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Escalating Cases of Cancer Worldwide to Catalyse the Market Growth of the Global Liquid Biopsy Industry
Liquid biopsy is an emerging tumour analysing method that is steadily gaining precedence in the market. This is mainly due to the rampant spread of cancer worldwide. According to the WHO statistics, cancer is a leading cause of death, with more than 10 million deaths recorded in 2020. Furthermore, out of all the cancer variations, breast cancer is the most prevalent in the world. In this regard, the WHO defines the early detection of cancer and appropriate treatment as a strategic method in reducing the number of cancer fatalities, as in the early stages, many cancer variations can be cured. As a result, governments and many international agencies are introducing initiatives to implement and develop liquid biopsy methodologies. For example, the bloodPAC project, a US-based Blood Profiling Atlas in Cancer Consortium, published validation protocols for liquid biopsy, reviewed by the FDA, to develop and define industry standards for liquid biopsy. These factors are expected to aid the market growth in the forecast period.
Key Industry Players in the Global Liquid Biopsy Market
The report gives a detailed analysis of the following key players in the global liquid biopsy market, covering their competitive landscape, capacity, and latest developments like mergers, acquisitions, and investments, expansions of capacity, and plant turnarounds:
- Biocept, Inc.
- F. Qiagen N.V.
- Bio-Rad Laboratories, Inc.
- NeoGenomics Laboratories, Inc.
- Guardant Health, Inc.
- Others
The comprehensive EMR report provides an in-depth assessment of the industry based on the Porter's five forces model and SWOT analysis.
| REPORT FEATURES | DETAILS |
|---|---|
| Base Year | 2023 |
| Historical Period | 2018-2023 |
| Forecast Period | 2024-2032 |
| Scope of the Report | Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment- Application, Sample Type, Biomarker, Technology, Region |
| Breakup by Application | Therapy Selection for Metastatic Breast Cancer, Therapy Selection for Other Metastatic Cancer, Molecular Health Monitoring |
| Breakup by Sample Type | Blood Sample Based, Urine Sample Based, Others |
| Breakup by Biomarker | Circulating Tumor Cells, Circulating Tumor DNA, Exosomes |
| Breakup by Technology | Multi-Gene-Parallel Analysis Using NGS, Single Gene Analysis Using PCR Microarrays |
| Breakup by Region | North America, Europe, Asia Pacific, Latin America, Middle East and Africa |
| Market Dynamics | SWOT, Porter's Five Forces, Key Indicators for Price and Demand |
| Competitive Landscape | Market Structure, Company Profiles- Company Overview, Product Portfolio, Demographic Reach and Achievements, Certifications |
| Companies Covered | Biocept, Inc., F. Qiagen N.V., Bio-Rad Laboratories, Inc., NeoGenomics Laboratories, Inc., Guardant Health, Inc., Others |
| Report Price and Purchase Option | Explore our purchase options that are best suited to your resources and industry needs. |
| Delivery Format | Delivered as an attached PDF and Excel through email, with an option of receiving an editable PPT, according to the purchase option. |
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1 Preface
2 Report Coverage – Key Segmentation and Scope
3 Report Description
3.1 Market Definition and Outlook
3.2 Properties and Applications
3.3 Market Analysis
3.4 Key Players
4 Key Assumptions
5 Executive Summary
5.1 Overview
5.2 Key Drivers
5.3 Key Developments
5.4 Competitive Structure
5.5 Key Industrial Trends
6 Snapshot
6.1 Global
6.2 Regional
7 Opportunities and Challenges in the Market
8 Global Liquid Biopsy Market Analysis
8.1 Key Industry Highlights
8.2 Global Liquid Biopsy Market Historical Market (2018-2023)
8.3 Global Liquid Biopsy Market Forecast (2024-2032)
8.4 Global Liquid Biopsy Market by Application
8.4.1 Therapy Selection for Metastatic Breast Cancer
8.4.1.1 Historical Trend (2018-2023)
8.4.1.2 Forecast Trend (2024-2032)
8.4.2 Therapy Selection for Other Metastatic Cancer
8.4.2.1 Historical Trend (2018-2023)
8.4.2.2 Forecast Trend (2024-2032)
8.4.3 Molecular Health Monitoring
8.4.3.1 Historical Trend (2018-2023)
8.4.3.2 Forecast Trend (2024-2032)
8.5 Global Liquid Biopsy Market by Sample Type
8.5.1 Blood Sample Based
8.5.1.1 Historical Trend (2018-2023)
8.5.1.2 Forecast Trend (2024-2032)
8.5.2 Urine Sample Based
8.5.2.1 Historical Trend (2018-2023)
8.5.2.2 Forecast Trend (2024-2032)
8.5.3 Others
8.6 Global Liquid Biopsy Market by Biomarker
8.6.1 Circulating Tumor Cells
8.6.1.1 Historical Trend (2018-2023)
8.6.1.2 Forecast Trend (2024-2032)
8.6.2 Circulating Tumor DNA
8.6.2.1 Historical Trend (2018-2023)
8.6.2.2 Forecast Trend (2024-2032)
8.6.3 Exosomes
8.6.3.1 Historical Trend (2018-2023)
8.6.3.2 Forecast Trend (2024-2032)
8.7 Global Liquid Biopsy Market by Technology
8.7.1 Multi-Gene-Parallel Analysis Using NGS
8.7.1.1 Historical Trend (2018-2023)
8.7.1.2 Forecast Trend (2024-2032)
8.7.2 Single Gene Analysis Using PCR Microarrays
8.7.2.1 Historical Trend (2018-2023)
8.7.2.2 Forecast Trend (2024-2032)
8.8 Global Liquid Biopsy Market by Region
8.8.1 North America
8.8.1.1 Historical Trend (2018-2023)
8.8.1.2 Forecast Trend (2024-2032)
8.8.2 Europe
8.8.2.1 Historical Trend (2018-2023)
8.8.2.2 Forecast Trend (2024-2032)
8.8.3 Asia Pacific
8.8.3.1 Historical Trend (2018-2023)
8.8.3.2 Forecast Trend (2024-2032)
8.8.4 Latin America
8.8.4.1 Historical Trend (2018-2023)
8.8.4.2 Forecast Trend (2024-2032)
8.8.5 Middle East and Africa
8.8.5.1 Historical Trend (2018-2023)
8.8.5.2 Forecast Trend (2024-2032)
9 North America Liquid Biopsy Market Analysis
9.1 United States of America
9.1.1 Historical Trend (2018-2023)
9.1.2 Forecast Trend (2024-2032)
9.2 Canada
9.2.1 Historical Trend (2018-2023)
9.2.2 Forecast Trend (2024-2032)
10 Europe Liquid Biopsy Market Analysis
10.1 United Kingdom
10.1.1 Historical Trend (2018-2023)
10.1.2 Forecast Trend (2024-2032)
10.2 Germany
10.2.1 Historical Trend (2018-2023)
10.2.2 Forecast Trend (2024-2032)
10.3 France
10.3.1 Historical Trend (2018-2023)
10.3.2 Forecast Trend (2024-2032)
10.4 Italy
10.4.1 Historical Trend (2018-2023)
10.4.2 Forecast Trend (2024-2032)
10.5 Others
11 Asia Pacific Liquid Biopsy Market Analysis
11.1 China
11.1.1 Historical Trend (2018-2023)
11.1.2 Forecast Trend (2024-2032)
11.2 Japan
11.2.1 Historical Trend (2018-2023)
11.2.2 Forecast Trend (2024-2032)
11.3 India
11.3.1 Historical Trend (2018-2023)
11.3.2 Forecast Trend (2024-2032)
11.4 ASEAN
11.4.1 Historical Trend (2018-2023)
11.4.2 Forecast Trend (2024-2032)
11.5 Australia
11.5.1 Historical Trend (2018-2023)
11.5.2 Forecast Trend (2024-2032)
11.6 Others
12 Latin America Liquid Biopsy Market Analysis
12.1 Brazil
12.1.1 Historical Trend (2018-2023)
12.1.2 Forecast Trend (2024-2032)
12.2 Argentina
12.2.1 Historical Trend (2018-2023)
12.2.2 Forecast Trend (2024-2032)
12.3 Mexico
12.3.1 Historical Trend (2018-2023)
12.3.2 Forecast Trend (2024-2032)
12.4 Others
13 Middle East and Africa Liquid Biopsy Market Analysis
13.1 Saudi Arabia
13.1.1 Historical Trend (2018-2023)
13.1.2 Forecast Trend (2024-2032)
13.2 United Arab Emirates
13.2.1 Historical Trend (2018-2023)
13.2.2 Forecast Trend (2024-2032)
13.3 Nigeria
13.3.1 Historical Trend (2018-2023)
13.3.2 Forecast Trend (2024-2032)
13.4 South Africa
13.4.1 Historical Trend (2018-2023)
13.4.2 Forecast Trend (2024-2032)
13.5 Others
14 Market Dynamics
14.1 SWOT Analysis
14.1.1 Strengths
14.1.2 Weaknesses
14.1.3 Opportunities
14.1.4 Threats
14.2 Porter’s Five Forces Analysis
14.2.1 Supplier’s Power
14.2.2 Buyer’s Power
14.2.3 Threat of New Entrants
14.2.4 Degree of Rivalry
14.2.5 Threat of Substitutes
14.3 Key Indicators for Demand
14.4 Key Indicators for Price
15 Value Chain Analysis
16 Competitive Landscape
16.1 Market Structure
16.2 Company Profiles
16.2.1 Biocept, Inc.
16.2.1.1 Company Overview
16.2.1.2 Product Portfolio
16.2.1.3 Demographic Reach and Achievements
16.2.1.4 Certifications
16.2.2 F. Qiagen N.V.
16.2.2.1 Company Overview
16.2.2.2 Product Portfolio
16.2.2.3 Demographic Reach and Achievements
16.2.2.4 Certifications
16.2.3 Bio-Rad Laboratories, Inc.
16.2.3.1 Company Overview
16.2.3.2 Product Portfolio
16.2.3.3 Demographic Reach and Achievements
16.2.3.4 Certifications
16.2.4 NeoGenomics Laboratories, Inc.
16.2.4.1 Company Overview
16.2.4.2 Product Portfolio
16.2.4.3 Demographic Reach and Achievements
16.2.4.4 Certifications
16.2.5 Guardant Health, Inc.
16.2.5.1 Company Overview
16.2.5.2 Product Portfolio
16.2.5.3 Demographic Reach and Achievements
16.2.5.4 Certifications
16.2.6 Others
17 Key Trends and Developments in the Market
List of Key Figures and Tables
1. Global Liquid Biopsy Market: Key Industry Highlights, 2018 and 2032
2. Global Liquid Biopsy Historical Market: Breakup by Application (USD Million), 2018-2023
3. Global Liquid Biopsy Market Forecast: Breakup by Application (USD Million), 2024-2032
4. Global Liquid Biopsy Historical Market: Breakup by Sample Type (USD Million), 2018-2023
5. Global Liquid Biopsy Market Forecast: Breakup by Sample Type (USD Million), 2024-2032
6. Global Liquid Biopsy Historical Market: Breakup by Biomarker (USD Million), 2018-2023
7. Global Liquid Biopsy Market Forecast: Breakup by Biomarker (USD Million), 2024-2032
8. Global Liquid Biopsy Historical Market: Breakup by Technology (USD Million), 2018-2023
9. Global Liquid Biopsy Market Forecast: Breakup by Technology (USD Million), 2024-2032
10. Global Liquid Biopsy Historical Market: Breakup by Region (USD Million), 2018-2023
11. Global Liquid Biopsy Market Forecast: Breakup by Region (USD Million), 2024-2032
12. North America Global Liquid Biopsy Historical Market: Breakup by Country (USD Million), 2018-2023
13. North America Global Liquid Biopsy Market Forecast: Breakup by Country (USD Million), 2024-2032
14. Europe Global Liquid Biopsy Historical Market: Breakup by Country (USD Million), 2018-2023
15. Europe Global Liquid Biopsy Market Forecast: Breakup by Country (USD Million), 2024-2032
16. Asia Pacific Global Liquid Biopsy Historical Market: Breakup by Country (USD Million), 2018-2023
17. Asia Pacific Global Liquid Biopsy Market Forecast: Breakup by Country (USD Million), 2024-2032
18. Latin America Global Liquid Biopsy Historical Market: Breakup by Country (USD Million), 2018-2023
19. Latin America Global Liquid Biopsy Market Forecast: Breakup by Country (USD Million), 2024-2032
20. Middle East and Africa Global Liquid Biopsy Historical Market: Breakup by Country (USD Million), 2018-2023
21. Middle East and Africa Global Liquid Biopsy Market Forecast: Breakup by Country (USD Million), 2024-2032
22. Global Liquid Biopsy Market Structure
Key Questions Answered in the Report
In 2023, the market attained a value of nearly USD USD 2,269.81 million.
The market is projected to grow at a CAGR of 22% between 2024 and 2032.
The major market drivers include the surging prevalence of cancer and rapid technological advancements.
The key trends guiding the market growth include improving healthcare infrastructure and the increasing development of innovative liquid biopsy methods.
The major regions in the market are North America, Latin America, Europe, the Middle East and Africa, and the Asia Pacific.
The various applications of liquid biopsy are therapy selection for metastatic breast cancer, therapy selection for other metastatic cancer, and molecular health monitoring.
The different sample types considered in the market report include blood sample based and urine sample based, among others.
The significant biomarkers of liquid biopsy in the market are circulating tumour cells, circulating tumour DNA, and exosomes.
The major technologies of liquid biopsy in the market are multi-gene-parallel analysis using NGS and single gene analysis using PCR microarrays.
The major players in the market are Biocept, Inc., F. Qiagen N.V., Bio-Rad Laboratories, Inc., NeoGenomics Laboratories, Inc., and Guardant Health, Inc., among others.
Analyst Review
The global liquid biopsy market attained a value of about USD 2,269.81 million in 2023, driven by the rising prevalence of cancer. Aided by the growing technological advancements, the market is expected to witness a further growth in the forecast period of 2024-2032, growing at a CAGR of 22%.
EMR’s meticulous research methodology delves deep into the market, covering the macro and micro aspects of the industry. Based on its applications, the liquid biopsy industry can be segmented into therapy selection for metastatic breast cancer, therapy selection for other metastatic cancer, and molecular health monitoring. By sample types, the industry can be divided into blood sample based and urine sample based, among others. On the basis of biomarkers, the industry is classified into circulating tumour cells, circulating tumour DNA, and exosomes. Based on technology, the market is bifurcated into multi-gene-parallel analysis using NGS and single gene analysis using PCR microarrays. The major regional markets for the liquid biopsy are North America, Latin America, Europe, the Middle East and Africa, and the Asia Pacific. The key players in the above market include Biocept, Inc., F. Qiagen N.V., Bio-Rad Laboratories, Inc., NeoGenomics Laboratories, Inc., and Guardant Health, Inc., among others.
EMR’s research methodology uses a combination of cutting-edge analytical tools and the expertise of their highly accomplished team, thus, providing their customers with market insights that are accurate, actionable, and help them remain ahead of their competition.
Purchase Options
Call us on
Purchase Full Report
Mini Report
$1699
-
Selected Sections, One User
-
Printing Not Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Single User License
$2799
-
All Sections, One User
-
One Print Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Five User License
$3999
-
All Sections, Five Users
-
Five Prints Allowed
-
Email Delivery in PDF
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Corporate License
$4999
-
All Sections, Unlimited Users
-
Unlimited Prints Allowed
-
Email Delivery in PDF + Excel
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Any Question? Speak With An Analyst
View A Sample
Did You Miss Anything, Ask Now
Why Expert Market Research?
Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.
NEWSLETTER